Eric Hilmes, PA
Medical · Las Vegas, NVNPI 1902050388
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,224 of the $14,793 with a category attached, or 82.6%. 29 manufacturers reported payments, led by AbbVie at 27.6% of the total. Reporting peaked in 2022 at $4,578 and has fallen 64.2% since, to $1,640 in 2025. Among medical clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 452 payments — averaging $32.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- UCB, Inc.$1K
- Arcutis Biotherapeutics, Inc.$1K
- EPI Health, LLC$895
- Sun Pharmaceutical Industries Inc.$764
- Johnson & Johnson$695
- plus $6K from 23 others
What the payments were for
- Consulting fees$2,11014%
- Food & beverage$12,22483%
- Education$4583%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 121 | $4,076 |
| UCB, Inc. | 42 | $1,443 |
| Arcutis Biotherapeutics, Inc. | 37 | $1,192 |
| EPI Health, LLC | 2 | $895 |
| Sun Pharmaceutical Industries Inc. | 28 | $764 |
| Johnson & Johnson | 38 | $695 |
| Sanofi | 29 | $677 |
| Strata Skin Sciences, Inc. | 1 | $610 |
| Novartis | 23 | $595 |
| Journey Medical Corporation | 8 | $569 |
| Incyte Corporation | 14 | $456 |
| Dermavant Sciences, Inc. | 3 | $413 |
| Pfizer | 18 | $374 |
| LEO Pharma Inc. | 20 | $355 |
| Amgen | 16 | $322 |
| Galderma Laboratories, L.p. | 12 | $262 |
| Boehringer Ingelheim | 3 | $261 |
| Regeneron Healthcare Solutions, Inc. | 6 | $219 |
| Lilly USA, LLC | 9 | $179 |
| Revance Therapeutics, Inc. | 4 | $99 |
| VYNE Pharmaceuticals Inc. | 2 | $58 |
| Boston Scientific | 3 | $46 |
| Dermira, Inc. | 3 | $44 |
| Biofrontera Inc. | 3 | $43 |
| Almirall LLC | 2 | $41 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Merz North America, Inc. | 1 | $26 |
| Kaleo, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,793 in reported general payments places this provider in the 95th percentile of 250 medical providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 17 | $112,190 |
| Dupixent PenDupilumab | 17 | $62,775 |
| OtezlaApremilast | 12 | $54,738 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 71 | $4,135 |
| Betamethasone Dipropionate | 42 | $2,666 |
| Doxycycline Monohydrate | 64 | $1,804 |
| Ketoconazole | 90 | $1,360 |
| Tretinoin | 17 | $1,188 |
| Triamcinolone Acetonide | 87 | $938 |
| Clobetasol Propionate | 20 | $905 |
| Ciclopirox | 12 | $610 |
| Fluocinonide | 13 | $565 |
| Ammonium Lactate | 37 | $477 |
| Hydroxyzine Hcl | 28 | $356 |
| Finasteride | 33 | $344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $4,076 | $112,19017 claims |
| AmgenOtezla | $322 | $54,73812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 medical providers in Nevada.
Other medical in Las Vegas
- John NotabartoloLas Vegas$284K
- Rachel BowersLas Vegas$29K
- Spencer MeierLas Vegas$24K
- Megan WieselLas Vegas$19K
- Tai PhamLas Vegas$16K
- Wardon OjedapoLas Vegas$12K
- Melchor GochiocoLas Vegas$11K
- Keesha KaplanLas Vegas$11K
- Adelbert WadsworthLas Vegas$11K
- Isaac TunnellLas Vegas$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.